The Canadian government’s COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG) announced an $800,000 investment as part of a quest to better understand how to improve Canada’s identification and response to the adverse events people may experience following COVID-19 vaccination across 10 provinces. This is an extension of an existing vaccine safety initiative that was set up to offer public health information about adverse events following immunization for all vaccines authorized for use in adults and children in the nation. The funding propels a study forward, allowing a more methodical and systematic tracking of adverse events associated with the COVID-19 vaccines authorized in Canada. TrialSite applauds the effort.
Recognition of Problems
Although it may not seem like big news, this announcement is tacit recognition of mounting safety reports associated with vaccines that at least in America, are still considered investigational—that is, they are not formally approved or registered but authorized under emergency use in the nation to the south.
In Canada, Dr. Karina Top, Principal Investigator (PI) for this initiative as well as lead inve...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).